Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways

Objective To characterise the molecular pathways impacted by the pharmacologic effects of the Janus kinase (JAK) 1 and JAK2 inhibitor baricitinib in SLE.Methods In a phase II, 24-week, randomised, placebo-controlled, double-blind study (JAHH), RNA was isolated from whole blood in 274 patients and an...

Full description

Bibliographic Details
Main Authors: Daniel J Wallace, Michelle A Petri, Thomas Dörner, Stephanie de Bono, Robert J Benschop, Ernst R Dow, Damiano Fantini, Richard E Higgs, Guilherme Rocha, Brenda Crowe, Nicole L Byers, Maria E Silk, Robert W Hoffman
Format: Article
Language:English
Published: BMJ Publishing Group 2020-12-01
Series:Lupus Science and Medicine
Online Access:https://lupus.bmj.com/content/7/1/e000424.full

Internet

https://lupus.bmj.com/content/7/1/e000424.full

Similar Items